Under the agreement, Hengrui will receive a total payment of up to $1.48B which includes an up front of $169M, milestone payments plus double-digit royalty on net sales in addition to technology transfer payments and an option to exclusively license SHR-A1904 for the treatment of cancer
Additionally, Merck KGaA will receive exclusive global rights (excl. mainland China) to develop, manufacture & commercialize HRS-1167 & SHR-A1904 whereas an option to co-promote them in mainland China
HRS-1167 (P-I) is a 2nd generation PARP1 inhibitor and SHR-A1904 (P-I in China, US & Australia) is a claudin 18.2 targeting ADC developed by Hengrui as cancer therapies
Ref: PR Newswire | Image: Merck KGaA
Related News:- Dewpoint Therapeutics Collaborated with Novo Nordisk to Identify Small Molecule Drugs for Insulin Resistance and Diabetes Progression
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
